deucravacitinib
bms
[' psa', '#2136', 'deucra', 'achieve,(-u achieve),(-u-achieve),(-uachieve)']
kavanaugh et al. tyk2i deucravacitinib in psa. nice breakdown of mda and its components over 16 weeks. mda achieved 23-24% with deucravacitinib at 16 weeks vs 8% with placebo #acr22 abstr#2136 
Rheumatologist @stjamesdublin , Associate Professor @tcddublin , Acute Medicine, Vasculitis, ILD, Retired @Emeunet Executive Committee member, @rheum_covid CASC